8-K/A: Standard BioTools Amends 8-K, Details SomaLogic Sale Pro Forma

Standard BioTools Inc. filed an amended 8-K to provide pro forma financial statements reflecting the completed sale of its SomaLogic business to Illumina for $363.7 million in net cash proceeds.

Summary

• Standard BioTools Inc. completed the sale of all equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd (collectively, the "Disposed Entities") to Illumina, Inc. on January 30, 2026.
• The Disposed Entities comprised the Company's SomaScan Business, including its SomaScan assay platform and related products and services.
• The Company retained its mass cytometry and microfluidics businesses, which were not part of the Transaction.
• Standard BioTools received net cash proceeds of approximately $363.7 million at the closing of the Transaction, subject to customary post-closing adjustments.
• The Company is eligible to receive contingent earnout payments of up to $75 million, with up to $25 million based on fiscal year 2025 performance and up to $50 million based on fiscal year 2026 performance, tied to specified revenue thresholds.
• Standard BioTools will also receive a 2% royalty on net revenues generated from sales of SOMAmer-based NGS library preparation kits for 10 years following the closing.
• A co-exclusive license to intellectual property relating to Single SOMAmer commercialization in singleplex affinity assays was also granted to Standard BioTools.
• As a result of the Transaction, the previous Collaboration Agreement between SomaLogic and Illumina Cambridge, Ltd. is terminated for Standard BioTools, and the Company will no longer be entitled to royalties or other payments under it.
• This Amendment No. 1 to Form 8-K/A includes unaudited pro forma condensed consolidated financial statements as of September 30, 2025, and for the nine months ended September 30, 2025, and the year ended December 31, 2024, reflecting the disposition.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, as the company has secured substantial cash proceeds, potential future earnouts and royalties, and can now focus on its remaining core businesses, leading to a significantly improved pro forma financial outlook for its continuing operations.

Positives

• A significant net cash proceeds of approximately $363.7 million was received at closing, substantially strengthening the Company's balance sheet.
• Potential for up to $75 million in contingent earnout payments provides future upside based on the performance of the divested assets.
• A 10-year 2% royalty stream on net revenues from SOMAmer-based NGS library preparation kits offers a long-term, recurring revenue opportunity.
• The Company retained a co-exclusive license to valuable intellectual property for Single SOMAmer commercialization in singleplex affinity assays.
• Pro forma financial statements for the year ended December 31, 2024, show a reduced net loss of $(87,789) thousand, a significant improvement compared to the as-reported $(138,885) thousand, indicating enhanced profitability for the continuing operations.
• The divestiture allows Standard BioTools to focus resources and strategic efforts on its core mass cytometry and microfluidics businesses.

Negatives

• The Company has divested its SomaScan business, including its assay platform and related products and services, which represented a portion of its revenue.
• The termination of the Collaboration Agreement between SomaLogic and Illumina Cambridge, Ltd. means Standard BioTools will no longer receive royalties or other payments from that agreement.
• An indemnification liability of $3,297 thousand was recognized, associated with potential future settlement of contingent payments to former SomaLogic employees.

Risks

• The total consideration received at closing is subject to customary post-closing adjustments as set forth in the Purchase Agreement.
• The contingent earnout payments of up to $75 million are dependent on the achievement of specified revenue thresholds for net revenue generated from SomaScan assay services and SOMAmer-based kit sales in fiscal years 2025 and 2026.
• An indemnification liability of $3,297 thousand has been recognized for potential future settlement of contingent payments to former employees of SomaLogic.

Future Outlook

Standard BioTools is eligible to receive up to $75 million in contingent earnout payments based on SomaScan revenue thresholds in fiscal years 2025 and 2026, and a 2% royalty on SOMAmer-based NGS library preparation kits for 10 years, providing potential future revenue streams and continued exposure to the divested business's success.

Management Comments

• Standard BioTools Inc. has duly caused this report to be signed on its behalf by Alex Kim, Chief Financial Officer.

Industry Context

StockSavvy.ai notes that this divestiture allows Standard BioTools to streamline its operations and focus on its core mass cytometry and microfluidics businesses, a strategic move common in the competitive life sciences and biotechnology sectors to optimize resource allocation and enhance shareholder value. The acquisition by Illumina further consolidates key technologies within the genomics and proteomics space, reflecting ongoing industry consolidation and specialization.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the transaction against global benchmarks.
• StockSavvy.ai would typically analyze the valuation multiples (e.g., revenue multiples, EBITDA multiples) of similar divestitures in the life sciences tools sector to determine if the $363.7 million cash proceeds plus potential earnouts and royalties represent a favorable outcome compared to industry precedents for assets of this nature.
• The strategic rationale of focusing on core competencies is a common industry practice aimed at improving operational efficiency and market positioning.

Legal Proceedings

• Recognition of an indemnification liability of $3,297 thousand associated with the potential future settlement of contingent payments to former employees of SomaLogic.

Related Party Transactions

• The sale of SomaLogic to Illumina, Inc. is notable given SomaLogic had a pre-existing Collaboration Agreement with Illumina Cambridge, Ltd. (an Illumina subsidiary), which is now terminated for Standard BioTools.

Stakeholder Impact

• Shareholders benefit from a significant cash infusion, potential future earnouts and royalties, and a clearer focus for the company's remaining operations, which could lead to improved profitability and valuation.
• Employees of the Disposed Entities are now part of Illumina. Standard BioTools recognized accrued expenses for retention bonuses related to the transaction.
• Customers of the SomaScan business will now be served by Illumina. Customers of Standard BioTools' mass cytometry and microfluidics businesses are unaffected, as these remain core to the Company.

Next Steps

• Completion of customary post-closing adjustments related to the sale of the Disposed Entities.
• Monitoring and achievement of specified revenue thresholds for contingent earnout payments in fiscal years 2025 and 2026.
• Collection of the 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for the next 10 years.
• Integration and utilization of the co-exclusive license for Single SOMAmer commercialization into ongoing business operations.

Key Dates

Recommendation

The divestiture of the SomaLogic business provides Standard BioTools with a substantial cash infusion of over $363 million, significantly strengthening its balance sheet. The company also retains potential upside through earnout payments and a 10-year royalty stream. The pro forma financials demonstrate a marked improvement in the net loss for continuing operations, suggesting a more focused and potentially profitable future. This strategic move allows the company to concentrate resources on its core mass cytometry and microfluidics businesses, which could unlock greater value. The strong cash position provides flexibility for strategic investments, debt reduction, or shareholder returns, making the stock an attractive 'buy' for long-term investors.

Keywords

Standard BioTools, SomaLogic, Illumina, divestiture, pro forma financials, SEC filing, 8-K/A, biotechnology, life sciences, M&A, mass cytometry, microfluidics, SomaScan, earnouts, royalties